Literature DB >> 22744259

A benign or malignant eyelid lump--can you tell? An unusual collision tumour highlighting the difficulty differentiating a hidrocystoma from a basal cell carcinoma.

Anuradha Jayaprakasam1, Cornelius Rene.   

Abstract

Hidrocystoma and basal cell carcinoma (BCC) are common eyelid lesions. The former is benign while the latter is malignant and can cause significant destruction of the adnexal structures, orbital invasion and visual loss. The authors describe a case of a 76-year-old female with a slow growing right upper lid lesion which was diagnosed as a hidrocystoma but excision biopsy revealed a collision tumour comprised of a BCC abutting a hidrocystoma in the same lesion. Cystic BCC can masquerade as hidrocystoma but there are no previous case reports of BCC coexisting with hidrocystoma in the same lesion. This case highlights the fact that apparently benign lesions, such as hidrocystomas, may actually be malignant or coexist with malignant pathology. Clinicians should have a low threshold for appropriate excision biopsy and histological examination of such lesions, especially if there are sinister features, such as lash loss, induration, pigmentation or a pearly appearance.

Entities:  

Mesh:

Year:  2012        PMID: 22744259      PMCID: PMC3448349          DOI: 10.1136/bcr.12.2011.5307

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Eyelid basal cell carcinoma developing in an epidermoid cyst: a previously unreported event.

Authors:  Frederick A Jakobiec; Fouad R Zakka; Mark P Hatton
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2010 Nov-Dec       Impact factor: 1.746

2.  A case of cutaneous collision tumour: the importance of photographic documentation and large incisional biopsy.

Authors:  P N Shams; J M Olver
Journal:  Eye (Lond)       Date:  2006-03-31       Impact factor: 3.775

3.  Collision sebaceous and basal cell carcinomas of the eyelid.

Authors:  Jaime Levy; Emanuela Cagnano; Daniel Benharroch; Tova Monos; Tova Lifshitz
Journal:  Ann Diagn Pathol       Date:  2006-06       Impact factor: 2.090

4.  Treatment of multiple apocrine hidrocystomas with trichloroacetic acid.

Authors:  Roger A Dailey; Stanley M Saulny; Robert N Tower
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2005-03       Impact factor: 1.746

Review 5.  Hidrocystomas--a brief review.

Authors:  Khashayar Sarabi; Amor Khachemoune
Journal:  MedGenMed       Date:  2006-09-06

Review 6.  Clinicopathological features of eyelid skin tumors. A retrospective study of 5504 cases and review of literature.

Authors:  Manuel Deprez; Sylvie Uffer
Journal:  Am J Dermatopathol       Date:  2009-05       Impact factor: 1.533

7.  Cystic basal cell carcinoma or hidrocytoma? The use of an excisional biopsy in a histopathologically challenging case.

Authors:  Tamy B H Buckel; Klaus F Helm; Michael D Ioffreda
Journal:  Am J Dermatopathol       Date:  2004-02       Impact factor: 1.533

8.  Non-Hodgkin lymphoma and Kaposi sarcoma in an eyelid of a patient with acquired immunodeficiency syndrome. Multiple viruses in pathogenesis.

Authors:  M Tunc; M L Simmons; D H Char; B Herndier
Journal:  Arch Ophthalmol       Date:  1997-11

Review 9.  Cutaneous collision tumors. An analysis of 69 cases and review of the literature.

Authors:  A S Boyd; R P Rapini
Journal:  Am J Dermatopathol       Date:  1994-06       Impact factor: 1.533

10.  Basal cell-signet-ring squamous cell carcinoma of the eyelid.

Authors:  Alan D Proia; M Angelica Selim; Jason C Reutter; John J Michon
Journal:  Arch Pathol Lab Med       Date:  2006-03       Impact factor: 5.534

  10 in total
  2 in total

Review 1.  Oculoplastic aspects of ocular oncology.

Authors:  C Rene
Journal:  Eye (Lond)       Date:  2012-11-30       Impact factor: 3.775

2.  Characterization of a murine xenograft model for contrast agent development in breast lesion malignancy assessment.

Authors:  Tsung-Hsien Yen; Gi-Da Lee; Jyn-Wen Chai; Jiunn-Wang Liao; Jia-Yu Lau; Li-Che Hu; Kuo-Chih Liao
Journal:  J Biomed Sci       Date:  2016-05-17       Impact factor: 8.410

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.